Insider · CIK 0001400977
James E Dentzer
Files at IMNN (Imunon, Inc.), CRIS (CURIS INC). First filing -, latest -.
In brief
James E Dentzer files SEC Form 4 as CEO, president and director at IMNN (Imunon, Inc.), and also at CRIS (CURIS INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James E Dentzer has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | IMNN Imunon, Inc. | AGrant or award Common Stock | +6,934 | $1.59 | $11k | 21,897 | Aug 4, 2026 |
| Jul 7, 2026 | CRIS CURIS INC | AGrant or award Employee stock option (right to buy)derivative | +110,090 | $5.29 | $582k | 110,090 | Jul 9, 2026 |
| May 22, 2026 | IMNN Imunon, Inc. | AGrant or award Common Stock | +11,148 | $2.20 | $25k | 14,963 | May 27, 2026 |
| Mar 20, 2026 | CRIS CURIS INC | CConversion Common Stock | +133,333 | - | - | 148,730 | Mar 23, 2026 |
| Mar 20, 2026 | CRIS CURIS INC | CConversion Series B Convertible Preferred Stockderivative | -100 | - | - | 0 | Mar 23, 2026 |
| Mar 17, 2026 | CRIS CURIS INC | AGrant or award Series B Convertible Preferred Stockderivative | +100 | - | - | 100 | Mar 18, 2026 |
| Mar 17, 2026 | CRIS CURIS INC | AGrant or award Series A Warrant (right to buy)derivative | +133,333 | - | - | 133,333 | Mar 18, 2026 |
| Mar 17, 2026 | CRIS CURIS INC | AGrant or award Series B Warrant (right to buy)derivative | +133,333 | - | - | 133,333 | Mar 18, 2026 |
| Mar 17, 2026 | CRIS CURIS INC | AGrant or award Series C Warrant (right to buy)derivative | +133,333 | - | - | 133,333 | Mar 18, 2026 |
| Jan 2, 2026 | IMNN Imunon, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +4,405 | $0.00 | $0 | 4,405 | Jan 6, 2026 |
| Aug 4, 2025 | IMNN Imunon, Inc. | AGrant or award Common Stock | +3,318 | $9.20 | $31k | 3,318 | Aug 6, 2025 |
| Aug 4, 2025 | IMNN Imunon, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +250 | $0.00 | $0 | 250 | Aug 6, 2025 |
| May 20, 2025 | CRIS CURIS INC | AGrant or award Employee stock option (right to buy)derivative | +360,000 | $3.13 | $1.1M | 360,000 | May 22, 2025 |
| Mar 14, 2025 | IMNN Imunon, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,750 | $0.00 | $0 | 3,750 | Mar 18, 2025 |
| Jan 28, 2025 | CRIS CURIS INC | AGrant or award Employee stock option (right to buy)derivative | +40,000 | $3.13 | $125k | 40,000 | Jan 30, 2025 |
Questions about James E Dentzer
Answered from the filings on this page, as of the latest one.
Is James E Dentzer buying or selling?
James E Dentzer has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James E Dentzer's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James E Dentzer has 0.
Where does James E Dentzer file Form 4?
James E Dentzer has filed Form 4 at IMNN (Imunon, Inc.); CRIS (CURIS INC) as President & CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.